Abstract Details

Title Clinical Characteristics of Pathologically Confirmed Parkinson Disease Patients with Freezing of Gait

Topic Movement Disorders

Presentation(s) P06 - (-)

Poster/Presentation
Number 099

Objective

Background BACKGROUND: 50-80% of PD patients reportedly have FOG, leading to impaired mobility, falls and decreased quality of life. Disease severity, initial gait or speech abnormalities, levodopa induced dyskinesias (LID), early morning dystonia and postural instability have previously been associated with FOG. We analyzed the clinical characteristics of patients with FOG in pathologically confirmed PD.

Design/Methods DESIGN/METHODS: Retrospective chart review of patients with a pathologic diagnosis of PD was undertaken. FOG was defined as a score of 1 or more on Question 13 of the Unified Parkinson's Disease Rating Scale (UPDRS) or FOG documented on examination by a movement disorder specialist. Serial office notes and UPDRS scales were used to determine progression of motor and non-motor symptoms of PD.

Results RESULTS: Out of 25 available patient charts, 21 patients had FOG. Mean onset of FOG from initial motor symptom was 9 years. The four patients without FOG were followed for a mean of 10 years (range 8-11). 90% of patients with FOG also had postural instability, 45% LID, 95% memory impairment, 81% hallucinations, and 52% orthostasis. Patients with early-FOG (mean 6 years to FOG) had earlier postural instability (5 vs. 11 years), memory impairment (6 vs. 10 years), and hallucinations (8 vs. 14 years) compared to those with late-FOG (mean 13 years to FOG).

Conclusions CONCLUSIONS: FOG may be more common in PD with autopsy proven PD than previously reported. Early-FOG was associated with earlier onset of postural instability, memory impairment and hallucinations, of which the latter two are potential clinical markers of cortical Lewy bodies. Detailed pathologic evaluation of this cohort may help gain insight into anatomical regions of interest in the pathogenesis of FOG.

Authors/Disclosures
Tuhin Virmani, MD, PhD, FAAN (University of Arkansas for Medical Sciences) PRESENTER	The institution of Dr. Virmani has received research support from Parkinson's Foundation.
	No disclosure on file
Stanley Fahn, MD, FAAN	Dr. Fahn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Stoparkinson Healthcare Systems, LLC; . Dr. Fahn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin Inc . Dr. Fahn has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Publishers . Dr. Fahn has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Kirkland & Ellis. Dr. Fahn has received publishing royalties from a publication relating to health care.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital)	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.

��ɫ��

��ɫ��